Dr.Giralt of discusses the role of transplant. - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission

Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission image

Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission

Podcast
event Sep 20, 2013 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Dr. Sergio Giralt, MD Memorial Sloan-Kettering Cancer Center

Interview date: September 20, 2013

Dr. Sergio Giralt discusses the role of transplant as consolidation therapy and his current study of how the various approaches relate to a patient's cytogenetics.  He shares his experience showing high-dose melphalan with an autologous transplant is still the best way of achieving long-term disease control and how the road to cure goes through complete remission. He discusses the 5 stages of transplantation and describes how he is working to use newer combinations to both improve the effectiveness of transplants but also to reduce the time to recovery and side effects for patients, with the goal to make transplantation as tolerable as regular chemotherapy. He shares studies at Memorial Sloan-Kettering that are working to eliminate host vs. graft disease for allogeneic transplant and why young, high-risk myeloma patients may want to consider that option. He describes new approaches at Memorial targeting gene mutations (like BRAF and MET gene mutations) and how a vaccine approach is just beginning. He describes the near future of genetic-specific trials that are just beginning in high-risk myeloma, but that they require national support so that one particular study can target a sufficient number of patients.  He stresses the importance of patient participation in clinical trials to push forward new and better therapies in myeloma.

Schedule & Agenda

Event panelist Dr Sergio Giralt & Jenny Ahlstrom
11:00 AM
Discussion
Dr Sergio Giralt & Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest B-Cell Lymphoma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.